ATE234278T1 - Aminosäurederivate als inhibitoren für extrazellulären matrix-metalloproteasen und der freisetzung von tnf alpha - Google Patents

Aminosäurederivate als inhibitoren für extrazellulären matrix-metalloproteasen und der freisetzung von tnf alpha

Info

Publication number
ATE234278T1
ATE234278T1 AT98922850T AT98922850T ATE234278T1 AT E234278 T1 ATE234278 T1 AT E234278T1 AT 98922850 T AT98922850 T AT 98922850T AT 98922850 T AT98922850 T AT 98922850T AT E234278 T1 ATE234278 T1 AT E234278T1
Authority
AT
Austria
Prior art keywords
inhibitors
release
amino acid
acid derivatives
extracellular matrix
Prior art date
Application number
AT98922850T
Other languages
English (en)
Inventor
Christian Jeanpetit
Didier Prigent
Pierre-Andre Settembre
Marie-Michele Trancart
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE234278T1 publication Critical patent/ATE234278T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98922850T 1997-04-22 1998-04-21 Aminosäurederivate als inhibitoren für extrazellulären matrix-metalloproteasen und der freisetzung von tnf alpha ATE234278T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9704971A FR2762315B1 (fr) 1997-04-22 1997-04-22 Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
PCT/FR1998/000801 WO1998047863A1 (fr) 1997-04-22 1998-04-21 DERIVES D'AMINO-ACIDES INHIBITEURS DES METALLOPROTEASES DE LA MATRICE EXTRACELLULAIRE ET DE LA LIBERATION DU TNF $g(a)

Publications (1)

Publication Number Publication Date
ATE234278T1 true ATE234278T1 (de) 2003-03-15

Family

ID=9506187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98922850T ATE234278T1 (de) 1997-04-22 1998-04-21 Aminosäurederivate als inhibitoren für extrazellulären matrix-metalloproteasen und der freisetzung von tnf alpha

Country Status (13)

Country Link
US (1) US6344457B1 (de)
EP (1) EP0977730B1 (de)
AR (1) AR013077A1 (de)
AT (1) ATE234278T1 (de)
AU (1) AU7534698A (de)
CA (1) CA2287565A1 (de)
CO (1) CO4950539A1 (de)
DE (1) DE69812082T2 (de)
ES (1) ES2194319T3 (de)
FR (1) FR2762315B1 (de)
TN (1) TNSN98052A1 (de)
WO (1) WO1998047863A1 (de)
ZA (1) ZA983390B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101663T2 (tr) 1998-12-10 2001-11-21 F.Hoffmann-La Roche Ag Pro-kollajen c-proteinaz inhibitörleri
EP1159273A1 (de) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Verbindungen, verwendbar als reversible inhibitoren von cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
EP2295081B1 (de) 2001-06-26 2018-10-31 Amgen Inc. Antikörper gegen OPGL
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
EP2287326A1 (de) 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Verfahren zur Protein-Produktion in Hefe
EP1737499A4 (de) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc Behandlung von chronisch obstruktiver lungenerkrankung durch inhalation von niedrigen dosen eines proteasehemmers
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
EP2586445A1 (de) * 2005-04-15 2013-05-01 University Of North Carolina At Chapel Hill Verfahren zur Ermöglichung des Überlebens von Nervenzellen mit Neurotrophin-Mimetika
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
JP2012519703A (ja) * 2009-03-06 2012-08-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ニューロトロフィン・ミメティック及びその使用
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
EP3470402B1 (de) 2009-11-12 2021-01-06 Pharmatrophix Inc. Kristalline formen aus neurotrophinmimetischen verbindungen und deren salzen
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
WO1997003966A1 (en) * 1995-07-19 1997-02-06 British Biotech Pharmaceuticals Limited N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors

Also Published As

Publication number Publication date
AR013077A1 (es) 2000-12-13
EP0977730A1 (de) 2000-02-09
FR2762315B1 (fr) 1999-05-28
EP0977730B1 (de) 2003-03-12
DE69812082T2 (de) 2003-11-06
CO4950539A1 (es) 2000-09-01
US6344457B1 (en) 2002-02-05
ZA983390B (en) 1999-02-09
ES2194319T3 (es) 2003-11-16
WO1998047863A1 (fr) 1998-10-29
CA2287565A1 (fr) 1998-10-29
TNSN98052A1 (fr) 2005-03-15
AU7534698A (en) 1998-11-13
DE69812082D1 (de) 2003-04-17
FR2762315A1 (fr) 1998-10-23

Similar Documents

Publication Publication Date Title
ATE234278T1 (de) Aminosäurederivate als inhibitoren für extrazellulären matrix-metalloproteasen und der freisetzung von tnf alpha
ATE226590T1 (de) Phosphinsäureamide als matrix metalloprotease inhibitoren
DE69820906D1 (de) Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
ATE232881T1 (de) Heterocyclen als inhibitoren der leukozytenadhäsion und vla-4-antagonisten
ATE244725T1 (de) Heterocyclen als inhibitoren der leukozytenadhäsion und vla-4-antagonisten
DE59703869D1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
ATE277895T1 (de) 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
FI972062A7 (fi) Substituoituja 4-biaryylivoi- tai 5-biaryylipentaanihappoja ja johdannaisia matriisimetalliproteaasi-inhibiittoreina
DE69836346D1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
EE9800425A (et) Uued aminohappe derivaadid ja nende kasutamine trombiini inhibiitoritena
NO990184D0 (no) Fosfintbaserte inhibitorer for mtriks-metalloproteaser
EE9900600A (et) Uued amidinoderivaadid ja nende kasutamine trombiini inhibiitoritena
DE50002364D1 (de) Abgewandelte aminosäureamide als cgrp antagonisten
EP1478735A4 (de) Verfahren zur induktion der differenzierung von monozyten zu funktionellen dendritischen zellen und solche dendritischen zellen enthaltende immuntherapeutische zusammensetzungen
EE9900006A (et) Uued amidinoderivaadid ja nende kasutamine trombiini inhibiitoritena
DE60026508D1 (de) Verwendungen von ppar-gamma-agonisten in neutrophil-verursachten erkrankungen
ATE366110T1 (de) Verwendung von inhibitoren des renin-angiotensin systems
DE69811223D1 (de) N-triazolyl-2-indolcarbonsäureamide und ihre verwendung als cck-a agonisten
NO973551L (no) Indoler med brostruktur som matriksmetallproteaseinhibitorer
ATE497786T1 (de) Zusammensetzungen und kits zur erhöhung der abgabe von therapeutischen mitteln an zellen
DE69801878D1 (de) Verwendung von Oxamatderivaten als Depigmentierungsmittel
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
TR199501429A2 (tr) Matriks metaloproteaz inhibitörlerinin yerine gecen 4-biarilpentanoik asitleri ve türevleri
ATE205822T1 (de) Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren
ID24306A (id) Turunan asam kuinolin-2 karboksilat dan penggunaannya sebagai antagonis asam amino eksitatori

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties